Genentech

Mallinckrodt appoints new leaders following completion of Questcor acquisition

Thursday, August 28, 2014 02:07 PM

Mallinckrodt, an Ireland-based global specialty pharmaceutical company, has announced that Gary Phillips, M.D., current senior vice president and chief strategy officer, has been appointed senior vice president and president of the company’s autoimmune and rare disease business, which includes the commercial organization supporting H.P. Acthar Gel.

More... »

WIRB Copernicus Group

FDA approves Avastin to treat aggressive and late-stage cervical cancer

Friday, August 15, 2014 12:43 PM

The FDA has approved a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer.

More... »


Incyte, Genentech ink clinical trial agreement for cancer immunotherapies

Thursday, July 31, 2014 12:33 PM

Incyte has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech's PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC).

More... »

Genentech to acquire Seragon Pharmaceuticals

Wednesday, July 2, 2014 12:38 PM

Genentech, a member of the Roche Group, will acquire Seragon Pharmaceuticals, a privately held biotechnology company based in San Diego, Calif. Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. 

More... »

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »

Coherus Biosciences appoints Lisa M. Bell senior VP, Global Regulatory Affairs

Monday, May 12, 2014 12:41 PM

Coherus Biosciences, a biologics platform company delivering biosimilar therapeutics, has appointed Lisa M. Bell, Ph.D. senior vice president, Global Regulatory Affairs. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies.

More... »

U.S. cancer researchers launching five-drug personalized medicines trial

Monday, April 21, 2014 01:12 PM

U.S. cancer researchers plan to launch a five-drug clinical trial for patients with advanced lung cancer in mid-May, in a public-private collaboration between several major cancer organizations and five pharmaceutical companies that marks the second American multi-drug research program into personalized medicines to treat different cancers.

More... »

Genentech, PatientsLikeMe enter patient-centric research collaboration

Wednesday, April 9, 2014 12:24 PM

PatientsLikeMe, a patient network and a real-time research platform, has formed a five-year agreement with Genentech, a member of the Roche Group, to explore using PatientsLikeMe’s global online patient network to develop innovative ways to research patients’ real-world experiences with disease and treatment. The agreement is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company and provides PatientsLikeMe the opportunity to expand its patient network in oncology.

More... »

Mytrus launches innovation advisory board

Wednesday, March 19, 2014 12:43 PM

Mytrus, a provider of electronic informed consent and e-clinical technologies, has created a new Innovation Advisory Board comprised of industry experts to help shape the future of its clinical products and services.

More... »

FDA approves first medicine with Breakthrough Therapy designation

Monday, November 4, 2013 01:35 PM

Genentech, a member of the Roche Group, has announced that the FDA approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs